Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Key Healthcare Earnings for May 3: CVS, MYL, PFE

As Q1 earnings season continues, more and more companies are starting to post their earnings results. On Tuesday, three big names in the healthcare industry reported their quarterly earnings before the bell. Let’s take a look.

CVS Health Corp. CVS

The pharmacy company reported adjusted first quarter earnings per share of $1.18, beating the Zacks Consensus Estimate by 2 cents and increasing 3.5% year-over-year. Net revenues were up 18.9% year-over-year to $43.2 billion, surpassing our consensus estimate of $42.9 billion. Thanks to balanced growth, CVS reiterated its full-year 2016 guidance.

Mylan N.V. MYL

Mylan, a pharmaceutical company, reported Q1 earnings per share of $0.76 (excluding special items), beating the Zacks Consensus Estimate by a penny and increasing 9% from the year-ago quarter. Revenues increased 17% to $2.19 billion, but lagged behind the Zacks Consensus Estimate of $2.26 billion; the top line saw year-over-year growth thanks to solid revenue growth in its Generics segment.

Pfizer, Inc. PFE

One of the biggest names in the pharmaceutical sector, Pfizer reported first quarter earnings per share of $0.67, beating the Zacks Consensus Estimate of $0.55. Revenues of $13.005 billion also came in well above expectations, beating our consensus estimate of $11.971 billion. As a result of strong results, Pfizer now expects to earn $2.38-$2.48 per share on revenues of $51 billion-$53 billion for 2016.

Check out Q1 earnings' scorecard by sector so far:

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 DaysClick to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PFIZER INC (PFE): Free Stock Analysis Report
 
MYLAN NV (MYL): Free Stock Analysis Report
 
CVS HEALTH CORP (CVS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research